TransCode Therapeutics Inc

Research TransCode Therapeutics Inc (RNAZ) on Bullrun: market cap USD 4.81M. Explore financials, valuation history, model signals, and stock context.

Key Metrics

• TickerRNAZ
• ExchangeNASDAQ
• CountryUnited States
• SectorHealthcare
• IndustryBiotechnology
• CurrencyUSD
• Market capUSD 4.81M
• Financial periodFY2025
• Net income-USD 34.66M
• Free cash flow-USD 19.52M

Valuation Snapshot

latest market cap is USD 4.81M.

About TransCode Therapeutics Inc

TransCode Therapeutics, Inc., a clinical-stage company, develops immuno-oncology and RNA therapeutics for the treatment of high risk and advanced cancers. The company's therapeutic candidate comprises SEVIPROTIMUT-L for the adjuvant treatment of patients with Stages IIB and IIC melanoma that has completed Phase 2 clinical trial;

Frequently asked questions

What is TransCode Therapeutics Inc's market cap?

TransCode Therapeutics Inc's market capitalization is USD 4.81M.

What does TransCode Therapeutics Inc do?

TransCode Therapeutics, Inc., a clinical-stage company, develops immuno-oncology and RNA therapeutics for the treatment of high risk and advanced cancers.